T1D Monitoring
Consensus Guidelines
Co-published in Diabetes Care and Diabetologia, the first international type 1 diabetes monitoring consensus delineates clear guidance for health care professionals to track and treat people who test positive for diabetes autoantibodies.
Guidance was convened by Breakthrough T1D (formerly JDRF)
and developed in partnership with:
Advanced Technologies & Treatments for Diabetes (ATTD)
American Association of Clinical Endocrinology (AACE)
American Diabetes Association (ADA)
Association of Diabetes Care & Education Specialists (ADCES)
Endocrine Society
Australian Diabetes Society (ADS)
European Association for the Study of Diabetes (EASD)
International Society for Pediatric and Adolescent Diabetes (ISPAD)
...and 60 experts from 11 countries on 4 continents (including several from the Barbara Davis Center for Diabetes)
The detection of autoantibodies is currently the earliest indicator that an individual may develop T1D in their lifetime. The guidance — designed for non-specialists, primary care providers, and pediatricians who are most likely to care for individuals who test positive — defines how these patients should be monitored. Studies show that monitoring following T1D screening can significantly reduce the incidence of diabetes-related ketoacidosis (DKA) at diagnosis and allows those in early stages of T1D to receive disease management guidance, potentially delay the onset through disease-modifying therapy, and/or to enroll in clinical trials assessing effectiveness of novel therapies.